Rani Therapeutics Holdings Inc (RANI)vsVertex Pharmaceuticals Inc (VRTX)
RANI
Rani Therapeutics Holdings Inc
$1.14
+7.55%
HEALTHCARE · Cap: $139.82M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1000008% more annual revenue ($12.00B vs $1.20M). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
RANI
Avoid17
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for RANI.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -11.9% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : RANI
The strongest argument for RANI centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
RANI profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.41 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 17/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company focused on transforming the delivery of injectable therapeutics with its cutting-edge RaniPill™ technology, facilitating the oral administration of biologics. This proprietary platform is designed to enhance patient adherence and improve treatment outcomes, addressing key unmet needs in the healthcare sector. With a robust and diverse pipeline across various therapeutic areas, Rani Therapeutics is poised to disrupt traditional drug delivery systems while capitalizing on the growing demand for non-invasive alternatives. The company’s strategic partnerships and unwavering commitment to research and development underscore its potential for sustainable growth and significant impact within the pharmaceutical industry.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?